Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Virtual Reality-Assisted Cognitive Behavioral Therapy for Alcohol Dependence (CRAVR)

9 novembre 2021 mis à jour par: Anders Fink-Jensen, MD, DMSci, Psychiatric Centre Rigshospitalet

Virtual Reality-Assisted Cognitive Behavioral Therapy for Alcohol Dependence: A Randomized Controlled Trial (CRAVR)

The study is a single-blinded, randomized, controlled, 12 months clinical trial. The objective is to investigate the feasibility, effects and side-effects of virtual reality-assisted cognitive behavioral therapy (VR-CBT) vs. cognitive behavioral therapy (CBT) in patients with a diagnosis of alcohol dependence.

Aperçu de l'étude

Description détaillée

Recruitment of participants:

102 patients will be recruited from the Novaví outpatient clinics, where they will be informed orally and in writing about the research project and, if they are interested, an information meeting is booked. If patients show symptoms of abstinence, these are treated prior to the information meeting by doctors and nurses in Novaví. If the patient then wishes to participate and meets the inclusion criteria, informed consent is obtained and screening is performed using the questionnaires described later. Included patients will then be randomized to either:

  1. Virtual reality-assisted cognitive behavioral therapy (VR-CBT)
  2. Cognitive behavioral therapy (CBT) without VR (control group)

Screening:

At the screening sessions, patients' medical history is obtained, as well as their alcohol intake over the past 30 days recorded via Timeline Follow-Back (TLFB). Patients are also asked about previous alcohol dependence treatment and general information about psychosocial factors incl. education, work, marital status, and functional level using Global Assessment of functioning (GAF). In addition, alcohol-related problems are assessed using the Alcohol Users Identification Test (AUDIT), abstinence using the Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar), intake of other drugs using the Drug User Identification Test (DUDIT), and alcohol craving using the Penn Alcohol Craving Scale (PACS). The Becks questionnaires, Depression Inventory 2 (BDI-II) and Beck's Anxiety Inventory (BAI), are included to assess the degree of anxiety and depression, and in addition, tests of mental function are performed using the Screening for Cognitive Impairment in Psychiatry (SCIP).

Intervention:

Included participants will in collaboration with their therapist schedule a standard course of treatment based on national guidelines from health authorities. After inclusion, participants are randomized to either:

  1. 14 sessions of VR-CBT (Group A)
  2. 14 sessions of CBT without VR (Group B, control group)

The participants in group A are exposed to VR-simulated high-risk situations filmed in a restaurant, a pub, at home, at a party or at the supermarket, to trigger alcohol cravings and other high-risk induced reactions of which the participants are subsequently trained to handle by trained therapists using CBT-based techniques.

The participants in group B receive the same treatment without VR exposure. The will be 4 weeks of weekly-biweekly treatment, followed by 20-21 weeks of treatment every 2-3 weeks, which is in line with the standard treatment in the Novaví outpatient clinics. The intervention deviates from standard treatment, as none of the participants receive pharmaceutical alcohol treatment during the treatment period (6 months) except for abstinence treatment if needed.

Randomization and blinding:

After screening a patient (ensuring that all inclusion criteria and no exclusion criteria are met) the patient is included. Participants are randomly allocated to either VR-CBT og CBT, 51 participants in each group. Randomization takes place in REDCap, which is a secure web application for building and managing surveys and databases. Age, sex and alcohol consumption are stratified at the time of inclusion ('heavy drinking days' and alcohol consumption - evaluated by TLFB). The technical setup of the randomization tool is performed in close collaboration with an expert in statistics, which ensures correct functionality before starting the experiment. After randomization, the therapist ensures that the participant receives the correct treatment and performs the alcohol craving assessment during each VR-CBT session unblinded using visual analog score (VAS). The study staff conducting the remaining data collections and the entire data analysis remain blinded until the database is opened at the end of the study. In situations where it is necessary to break the blind, it is possible to change the user rights in REDCap and gain access to the randomization tools. With the randomization tools, it is possible to detect the treatment (VR-CBT or CBT) based on study ID and all activities performed in REDCap are registered in the program.

Follow-up:

Each participant must attend a follow-up visit 3, 6, and 12 months from inclusion, where data collection will take place using the before mentioned questionnaires. The follow-up visit will be approx. 1 hour.

Statistical analysis:

All statistical analyzes are performed using the intention-to-treat principle, where all patients who have become randomized and has received a minimum of 1 session of VR-CBT (group A) or CBT without VR (group B), is included in the analysis. Missing data are implemented through the multiple imputation method and the analyzes are performed in the program "R" with alpha = 0.05 and 2-sided test. All continuous effect measures are analyzed using ANOVA from baseline to most recent measurement, and categorical data are analyzed using chi2 analysis. All data distributions will be assessed for normality by visual inspection of histogram and by Q-Q plots. If data is not normally distributed, log transformation is performed, and if this is not successful, non-parametric testing is used.

Type d'étude

Interventionnel

Inscription (Anticipé)

102

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Frederiksberg
      • Copenhagen, Frederiksberg, Danemark, 2000
        • Recrutement
        • Novavi ambulatorierne
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 70 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Informed oral and written consent
  • Meets criteria for alcohol dependence syndrome according to International Classification of Diseases (ICD) 10, WHO & Diagnostic and Statistical Manual of Mental Disorder (DSM-5)
  • Age 18 - 70 years old (both included)
  • Minimum 5 'heavy drinking days' in the last month, which is defined as an alcohol intake above 60/48 grams or 5/4 items per. day for resp. men and women over the past 30 days

Exclusion Criteria:

  • Other active substance use defined by DUDIT score> 6 (for men)> 2 (for women) and meet the criteria for other drug dependence according to ICD-10 (excluding nicotine)
  • Does not speak or understand Danish
  • Mental retardation or known severe psychiatric illness or other condition where it is assessed that will interfere with participation eg severely impaired vision or hearing.
  • Medical alcohol treatment (disulfiram, acamprosate, naltrexone or nalmefen) within the latest 4 weeks and during the treatment period

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Thérapie cognitivo-comportementale (TCC)
La TCC est composée des éléments suivants : i) reconnaissance (ii) évitement et (iii) dépassement des envies de boire dans les situations à haut risque dans le but de prévenir les rechutes.
The active comparator receives 14 conventional cognitive behavioral therapy sessions with
Expérimental: Virtual Reality Cognitive Behavioral Therapy (VRCBT)
The VR exposure is performed to induce alcohol craving and high-risk induced reactions during the therapy session, in order to trigger a lifelike response to alcohol, while the therapist is present and able to train the participant in applying CBT-based coping strategies to deal with the alcohol cravings.
Participants in the intervention group will scheduled for 14 treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations in virtual reality. VR-assisted gradual exposure therapy is integrated as a part of CBT. I.e. VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Reduction in total alcohol consumption
Délai: Baseline, 6 months, 9 months, 12 months
Percent change in alcohol consumption, defined as "x" grams of alcohol for past 30 days. This will be registered using the Timeline-Follow-Back (TLFB) method.
Baseline, 6 months, 9 months, 12 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in heavy drinking days
Délai: Baseline, 6 months, 9 months, 12 months
Based on the past 30 days of alcohol consumption using time line follow-back (TLFB), heavy drinking days are evaluated. 1 heavy drinking day consists of alcohol consumption exceeding 60/48 grams for men and women respectively.
Baseline, 6 months, 9 months, 12 months
Change in Alcohol Users Identification Test (AUDIT) score
Délai: Baseline, 6 months, 9 months, 12 months
Screening for excessive drinking. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Change in Drug User Identification Test (DUDIT) score
Délai: Baseline, 6 months, 9 months, 12 months
Identification of individuals with drug-related problems. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Change in Penn Alcohol Craving Scale (PACS) score
Délai: Baseline, 6 months, 9 months, 12 months
Assessing alcohol craving. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Screening for Cognitive Impairment in Psychiatry (SCIP) score
Délai: Baseline, 6 months, 9 months, 12 months
The 20 minute test is a scale developed for screening cognitive deficits. Higher score = better outcome
Baseline, 6 months, 9 months, 12 months
Change in Global Assessment of functioning (GAF) score
Délai: Baseline, 6 months, 9 months, 12 months
GAF measures to what degree a person's symptoms affect their daily functioning on a scale of 0 to 100. Higher score = better outcome
Baseline, 6 months, 9 months, 12 months
Becks Anxiety Inventory (BAI) score
Délai: Baseline, 6 months, 9 months, 12 months
Measures the severity of anxiety. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Becks Depression Inventory 2 (BDI-II) score
Délai: Baseline, 6 months, 9 months, 12 months
Measures the severity of depression. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Simulator Sickness Questionnaire (SSQ)
Délai: Each of the 14 treatment sessions over 6 months
Measures whether participants experience symptoms of simulator sickness while in Virtual Reality. Higher score = worse outcome
Each of the 14 treatment sessions over 6 months
VR-induced craving on a visual analog scale (VAS)
Délai: Each of the 14 treatment sessions over 6 months
For each of the 6 VR-scenes, craving is evaluated before, during and after exposure as well as at the end of the therapy session
Each of the 14 treatment sessions over 6 months
Alcohol withdrawal symptoms
Délai: Evaluated at inclusion
Alcohol withdrawal symptoms are evaluated at inclusion. Higher score = worse outcome
Evaluated at inclusion
Qualitative assessment
Délai: After completion of a full treatment period of 6 months
15 patients and 5 therapists will be asked about advantages and disadvantages of using virtual reality
After completion of a full treatment period of 6 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

6 octobre 2021

Achèvement primaire (Anticipé)

1 mars 2024

Achèvement de l'étude (Anticipé)

1 mars 2024

Dates d'inscription aux études

Première soumission

27 juillet 2021

Première soumission répondant aux critères de contrôle qualité

10 septembre 2021

Première publication (Réel)

13 septembre 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 novembre 2021

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 novembre 2021

Dernière vérification

1 novembre 2021

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner